| # | Title | Journal | Year | Citations |
|---|
| 1 | Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor | Journal of Clinical Oncology | 2015 | 1,397 |
| 2 | Task Group 142 report: Quality assurance of medical acceleratorsa) | Medical Physics | 2009 | 1,217 |
| 3 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine | 2015 | 927 |
| 4 | Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Lancet Oncology, The | 2010 | 882 |
| 5 | The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk | Circulation: Arrhythmia and Electrophysiology | 2009 | 747 |
| 6 | Core Outcome Domains and Measures for Pediatric Acute and Chronic/Recurrent Pain Clinical Trials: PedIMMPACT Recommendations | Journal of Pain | 2008 | 718 |
| 7 | In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications | Journal of the American College of Cardiology | 2005 | 712 |
| 8 | Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict Death and Stroke | Circulation | 2003 | 690 |
| 9 | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group | Blood | 2016 | 686 |
| 10 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management | Leukemia | 2010 | 677 |
| 11 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study | Leukemia | 2012 | 664 |
| 12 | 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features | Arthritis Care and Research | 2011 | 658 |
| 13 | A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma | British Journal of Haematology | 2004 | 632 |
| 14 | The bone marrow microenvironment at single-cell resolution | Nature | 2019 | 624 |
| 15 | Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19 | JAMA - Journal of the American Medical Association | 2021 | 617 |
| 16 | Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy | Blood | 2007 | 563 |
| 17 | Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation | Blood | 2013 | 537 |
| 18 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial | Lancet, The | 2019 | 517 |
| 19 | Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation | Blood | 2013 | 507 |
| 20 | Comprehensive Clinical Assessment in Community Setting: Applicability of the MDS‐HC | Journal of the American Geriatrics Society | 1997 | 476 |
| 21 | First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers | Journal of Clinical Oncology | 2019 | 457 |
| 22 | HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices | Heart Rhythm | 2015 | 449 |
| 23 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial | Lancet, The | 2017 | 444 |
| 24 | 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry | Journal of the American College of Cardiology | 2017 | 429 |
| 25 | International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma | Leukemia | 2009 | 428 |
| 26 | Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets | Journal of Experimental Medicine | 2008 | 427 |
| 27 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation* | Critical Care Medicine | 2013 | 423 |
| 28 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study | Lancet Oncology, The | 2017 | 402 |
| 29 | Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 | JAMA Internal Medicine | 2021 | 385 |
| 30 | Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum | American Journal of Surgical Pathology | 2007 | 381 |
| 31 | First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma | Journal of Translational Medicine | 2018 | 376 |
| 32 | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Lancet Oncology, The | 2016 | 373 |
| 33 | Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results | Blood | 2015 | 349 |
| 34 | Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices) | European Heart Journal | 2014 | 347 |
| 35 | Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers | Journal of Clinical Oncology | 2002 | 343 |
| 36 | Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib | Leukemia | 2008 | 341 |
| 37 | Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer | Surgical Endoscopy and Other Interventional Techniques | 2006 | 333 |
| 38 | Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial | Lancet, The | 2018 | 324 |
| 39 | American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1 | Arthritis and Rheumatology | 2020 | 323 |
| 40 | American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2 | Arthritis and Rheumatology | 2021 | 314 |
| 41 | Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study | Annals of Oncology | 2009 | 302 |
| 42 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study | Lancet, The | 2020 | 299 |
| 43 | Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: A subgroup analysis of TRENDS | Heart Rhythm | 2011 | 296 |
| 44 | Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group | Leukemia | 2013 | 294 |
| 45 | BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia | Cancer Cell | 2014 | 292 |
| 46 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation | Blood | 2011 | 282 |
| 47 | Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 | JAMA Network Open | 2021 | 278 |
| 48 | Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype | Cancer | 2011 | 277 |
| 49 | Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma | Blood | 2018 | 276 |
| 50 | Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome | JAMA Neurology | 2021 | 276 |
